Login to Your Account

BIO 2016

Will biopharma deal-making brave the headwinds or retreat to 'wait-and-see'?

By Marie Powers
News Editor

Friday, June 10, 2016

Following a record-breaking year for deal-makers, 2016 isn't exactly off to the races. The drug pricing debate, magnified through the lens of a contentious Presidential campaign, and mounting pressure on the industry's blue chips to improve performance in the midst of a volatile stock market have placed heavy demands on partnering activity. In a super session on the final day of the BIO International Convention, a panel of veteran deal-makers debated whether big biopharmas will take a wait-and-see approach or throw caution to the wind and forge ahead with partnering and M&A.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription